Mylan N.V. (MYL) Stock Rating Upgraded by BidaskClub
Mylan N.V. (NASDAQ:MYL) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Thursday.
MYL has been the subject of several other research reports. Barclays PLC upgraded Mylan N.V. from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $47.00 to $50.00 in a research report on Monday, May 22nd. Cantor Fitzgerald initiated coverage on Mylan N.V. in a research report on Friday, June 16th. They issued a “neutral” rating and a $41.00 price objective for the company. Royal Bank Of Canada set a $41.00 price objective on Mylan N.V. and gave the stock a “hold” rating in a research report on Sunday, July 16th. Zacks Investment Research cut Mylan N.V. from a “hold” rating to a “sell” rating in a research report on Monday, May 15th. Finally, Wells Fargo & Company reiterated a “market perform” rating and issued a $40.00 price objective on shares of Mylan N.V. in a research report on Wednesday, May 31st. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $43.43.
Shares of Mylan N.V. (NASDAQ MYL) opened at 32.10 on Thursday. Mylan N.V. has a 1-year low of $29.39 and a 1-year high of $45.87. The company has a 50-day moving average of $33.17 and a 200-day moving average of $37.91. The firm has a market cap of $17.21 billion, a PE ratio of 25.95 and a beta of 1.31.
Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings data on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by $0.08. The business had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The company’s revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.16 EPS. Analysts predict that Mylan N.V. will post $4.52 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Mylan N.V. (MYL) Stock Rating Upgraded by BidaskClub” was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/10/mylan-n-v-myl-stock-rating-upgraded-by-bidaskclub.html.
A number of large investors have recently modified their holdings of MYL. BlackRock Inc. boosted its stake in Mylan N.V. by 3,447.5% in the 1st quarter. BlackRock Inc. now owns 38,822,643 shares of the company’s stock worth $1,513,696,000 after buying an additional 37,728,274 shares during the last quarter. Pzena Investment Management LLC acquired a new stake in Mylan N.V. in the 1st quarter worth about $283,158,000. Vanguard Group Inc. boosted its stake in Mylan N.V. by 12.0% in the 2nd quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock worth $1,276,432,000 after buying an additional 3,531,974 shares during the last quarter. TIAA CREF Investment Management LLC boosted its stake in Mylan N.V. by 187.3% in the 1st quarter. TIAA CREF Investment Management LLC now owns 4,315,668 shares of the company’s stock worth $168,268,000 after buying an additional 2,813,653 shares during the last quarter. Finally, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management acquired a new stake in Mylan N.V. in the 2nd quarter worth about $84,364,000. 71.97% of the stock is currently owned by hedge funds and other institutional investors.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.